← Leaderboards
Khalid Matrougui
Tulane University Of Louisiana
$5,557,211
Attributed
$5,557,211
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $836.7K · FY2008–23$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,557,211 · 6
By mechanism
R01$5,123,434 · 3
P20$433,777 · 3
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Samir S El-Dahr$10,425,237
- Luis Gabriel Navar$15,722,322
- Kailash N Pandey$11,062,222
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionEndothelial CellsBlood VesselsPathologyCardiovascular DiseasesMorbidity - Disease RateStructureCessation Of LifeVascular DiseasesMultidisciplinaryFunctional DisorderInflammatoryGenerationsInflammationNon-Insulin-Dependent Diabetes MellitusEtiologyDiabetic MouseEndoplasmic Reticulum StressKnockout MiceDiabetic PatientClinically SignificantCytokineCalcificationCardiovascular System
Grant awards (18)
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes$376,097
R01 · FY2023 · HL · contact PI
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension$358,121
R01 · FY2023 · HL · contact PI
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes$73,063
R01 · FY2023 · HL · contact PI
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension$16,879
R01 · FY2023 · HL · contact PI
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes$449,160
R01 · FY2022 · HL · contact PI
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension$375,000
R01 · FY2022 · HL · contact PI
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes$449,160
R01 · FY2021 · HL · contact PI
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension$375,000
R01 · FY2021 · HL · contact PI
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes$461,660
R01 · FY2020 · HL · contact PI
Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension$375,000
R01 · FY2020 · HL · contact PI
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes$355,336
R01 · FY2014 · HL · contact PI
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes$345,183
R01 · FY2013 · HL · contact PI
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes$368,775
R01 · FY2012 · HL · contact PI
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes$372,500
R01 · FY2011 · HL · contact PI
Mechanisms of Coronary Arteriolar Dysfunction in Type 2 Diabetes$372,500
R01 · FY2010 · HL · contact PI
MECHANISMS OF RESISTANCE ARTERY STRUCTURAL REMODELING IN HYPERTENSION$163,900
P20 · FY2010 · RR · contact PI
MECHANISMS OF RESISTANCE ARTERY STRUCTURAL REMODELING IN HYPERTENSION$138,143
P20 · FY2009 · RR · contact PI
MECHANISMS OF RESISTANCE ARTERY STRUCTURAL REMODELING IN HYPERTENSION$131,734
P20 · FY2008 · RR · contact PI